Auris Medical Holding Ltd. Banner Image

Auris Medical Holding Ltd. has reached its limit for free report views

Work for Auris Medical Holding Ltd.? Upgrade Your Profile and unlock all your annual reports.

Auris Medical Holding Ltd.

  • Ticker EARS
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Auris Medical Holding Ltd. Logo Image
  • 1-10 Employees
  • Based in Zug, Switzerland
Auris Medical is a biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in neurotology and CNS disorders. The Company is focused on the development of intranasal betahistine for the treatment of vertigo (AM-125, in Phase 2) and for the prevention of antipsychotic-induced weight gain and somnolence (AM-201, post Phase 1b). With AM-301More, the Company is developing a nasal spray for protection against airborne pathogens and allergens. In addition Auris Medical has two Phase 3 programs under development: Sonsuvi® (AM-111) for acute inner ear hearing loss and Keyzilen® (AM-101) for acute inner ear tinnitus. The Company was founded in 2003 and is headquartered in Hamilton, Bermuda with its main operations in Basel, Switzerland. The shares of Auris Medical Holding Ltd. trade on the NASDAQ Capital Market under the symbol “EARS.”
Auris Medical Holding Ltd.

Most Recent Annual Report

Auris Medical Holding Ltd. MOST RECENT 2019 Annual Report

Report Locked. Auris Medical Holding Ltd. has reached its limit for free report views.

Older/Archived Annual Reports